肿瘤患者间期和分裂期T淋巴细胞AgNORs的相关性分析

Correlative analysis of AgNORs between peripheral T lymphocyte nucleus and chromosome from patients with malignant tumor

目的:探讨肿瘤患者外周血T淋巴细胞间期核和分裂期染色体AgNORs的相关性及临床应用价值。方法:应用银染色技术及KL型图像分析系统,检测74例食管癌、68例原发性肝癌患者和40例对照组的T淋巴细胞间期核和分裂期染色体AgNORs,结果分别以银染核仁面积与细胞核面积的百分比值(I.S%)和AgNORs数/细胞表示。结果:①食管癌和原发性肝癌患者间期核AgNORs的I.S%(5.28±0.86和5.37±0.94)显著低于对照组(7.56±0.78)(P<0.01),分裂期染色体AgNORs数/细胞(5.64±0.45和5.75±0.49)也显著低于对照组(7.35±0.55)(P<0.01);②这两种指标在食管癌和原发性肝癌患者间均无显著性差异(P>0.05);③食管癌、原发性肝癌患者及对照组的这两种指标呈正相关,相关系数分别为0.82、0.80和0.87,均为P<0.001。结论:肿瘤患者外周血T淋巴细胞间期核AgNORs的I.S%和分裂期染色体AgNORs数/细胞具有相关性,二者均可作为肿瘤的辅助诊断指标,但前者能自动计数、检测方便,结果准确可靠,比后者更适合在临床推广应用。

Objective：To investigate the AgNORs＇ correlation between peripheral T lymphocyte nucleus and chromosome from the patients with tumor. Methods：Silver straining technique and KL image system were used to detect AgNORs of peripheral T lymphocyte nucleus and chromosome in 74 patients with esophageal carcinoma,68 patients with primary hepatic cancer,arid 40 healthy control. The results were expressed in the ratio of silver staining nucleolus area to nucleus area （I.S%） and the chromosome AgNORs counts （AgNORs counts/cell）. Results： ①The I.S% of AgNORs and the chromosome AgNORs counts in patients with esophageal carcinoma （5.28 ± 0.86,5.64 ± 0.45） and patients with primary hepatic cancer （5.37 ± 0.94,5.75 ± 0.49） were lower than those in healthy control（7.56,±0.78,7.35 ± 0.55）（P 〈 0.01 ）;②There was no statistical difference in I.S% of AgNORs and the chromosome AgNORs counts between patients with esophageal carcinoma and primary hepatic cancer（P 〉 0.05）; ③In patients with esophageal carcinoma, primary hepatic cancer,and the healthy control, the I.S% of AgNORs was positively correlated with the chromosome AgNORs counts. Correlation coefficeients were 0.85,0.80 and 0.87,respectively （P 〈 0.001 ）. Conclusion：The I.S% of AgNORs and the chromosome AgNORs counts in peripheral T lymphocytes can be served as two useful immunologic diagnostic makers, but the former presents a more convenient and credible approach for clinical application than the latter.